Literature DB >> 15936719

Death receptors, Fas and TRAIL receptors, are involved in human osteoclast apoptosis.

Sophie Roux1, Pascal Lambert-Comeau, Céline Saint-Pierre, Mariette Lépine, Bassem Sawan, Jean-Luc Parent.   

Abstract

Survival and apoptosis are crucial aspects of the osteoclast life cycle. Although osteoclast survival has been extensively studied, little is known about the mechanisms involved in human osteoclast apoptosis. In the present study, cord blood monocytes (CBMs) were used as the source of human osteoclast precursors. When cultured in the presence of M-CSF and RANKL, CBMs formed multinucleated cells that expressed RANK and calcitonin receptor, and were able to resorb bone. These cells expressed TRAIL receptors (R1-R4). Surprisingly, although TRAIL-receptor expression was not detectable in osteoclasts from normal bone, osteoclasts from myeloma specimens did express TRAIL receptors to a variable extent. Significantly, we have shown for the first time that this pathway is indeed functional in human osteoclasts, and that apoptosis occurred and was significantly greater in the presence of TRAIL. In addition, we have shown that a Fas-activating antibody is also able to induce osteoclast apoptosis, as did TGFbeta, whereas the survival factor M-CSF decreased apoptosis. Overall, these findings suggest that death receptors, TRAIL receptors and Fas, could be involved in osteoclast apoptosis in humans.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15936719     DOI: 10.1016/j.bbrc.2005.05.092

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  27 in total

Review 1.  Osteoimmunology: interactions of the bone and immune system.

Authors:  Joseph Lorenzo; Mark Horowitz; Yongwon Choi
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

Review 2.  RNA therapeutics targeting osteoclast-mediated excessive bone resorption.

Authors:  Yuwei Wang; David W Grainger
Journal:  Adv Drug Deliv Rev       Date:  2011-09-10       Impact factor: 15.470

3.  TRPV-5 mediates a receptor activator of NF-kappaB (RANK) ligand-induced increase in cytosolic Ca2+ in human osteoclasts and down-regulates bone resorption.

Authors:  Estelle Chamoux; Martine Bisson; Marcel Daniel Payet; Sophie Roux
Journal:  J Biol Chem       Date:  2010-06-11       Impact factor: 5.157

Review 4.  Targeting Fas in osteoresorptive disorders.

Authors:  Natasa Kovacic; Danka Grcevic; Vedran Katavic; Ivan Kresimir Lukic; Ana Marusic
Journal:  Expert Opin Ther Targets       Date:  2010-10       Impact factor: 6.902

5.  Bone Mass Is Compromised by the Chemotherapeutic Trabectedin in Association With Effects on Osteoblasts and Macrophage Efferocytosis.

Authors:  Benjamin P Sinder; Laura Zweifler; Amy J Koh; Megan N Michalski; Lorenz C Hofbauer; Jose Ignacio Aguirre; Hernan Roca; Laurie K McCauley
Journal:  J Bone Miner Res       Date:  2017-08-31       Impact factor: 6.741

6.  Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma.

Authors:  Agatha Labrinidis; Peter Diamond; Sally Martin; Shelley Hay; Vasilios Liapis; Irene Zinonos; Natalie A Sims; Gerald J Atkins; Cristina Vincent; Vladimir Ponomarev; David M Findlay; Andrew C W Zannettino; Andreas Evdokiou
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

7.  Gene expression profile in osteoclasts from patients with Paget's disease of bone.

Authors:  Laetitia Michou; Estelle Chamoux; Julie Couture; Jean Morissette; Jacques P Brown; Sophie Roux
Journal:  Bone       Date:  2009-11-17       Impact factor: 4.398

8.  Transforming growth factor-beta1 (TGF-beta1) induces human osteoclast apoptosis by up-regulating Bim.

Authors:  Nicolas Houde; Estelle Chamoux; Martine Bisson; Sophie Roux
Journal:  J Biol Chem       Date:  2009-07-01       Impact factor: 5.157

Review 9.  Osteoimmunology: cytokines and the skeletal system.

Authors:  Seoung-Hoon Lee; Tae-Soo Kim; Yongwon Choi; Joseph Lorenzo
Journal:  BMB Rep       Date:  2008-07-31       Impact factor: 4.778

10.  The p62 P392L mutation linked to Paget's disease induces activation of human osteoclasts.

Authors:  Estelle Chamoux; Julie Couture; Martine Bisson; Jean Morissette; Jacques P Brown; Sophie Roux
Journal:  Mol Endocrinol       Date:  2009-07-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.